Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Manganese chloride tetrahydrate - Ascelia Pharma

Drug Profile

Manganese chloride tetrahydrate - Ascelia Pharma

Alternative Names: CMC-001; Mangoral; Orviglance

Latest Information Update: 16 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CMC Contrast
  • Developer Ascelia Pharma
  • Class Contrast media; Heavy metals
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase III Liver disorders

Most Recent Events

  • 09 Aug 2023 Ascelia Pharma plans to discuss with the FDA regarding the significant intra-reader variability observed in image scoring in the phase III SPARKLE trial
  • 21 Jun 2023 Safety and efficacy data from a open-label trial in hepatically impaired participants was presented at the European Association for the Study of the Liver Congress, 2023 (EASL-2023)
  • 27 Feb 2023 Ascelia Pharma completes a phase III SPARKLE trial in Liver disorders (Diagnosis) in the US, Argentina, Colombia, Germany, Italy, Mexico, Poland, Russia, Sweden and Turkey (PO) (NCT04119843)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top